Crimson Publishers Publish With Us Reprints e-Books Video articles


Novel Approaches in Cancer Study

Aptamer Technology in the Targeted Delivery of Doxorubicin

  • Open or Close Sarah E Sheikh1, Clay Marsh2 and Duaa Dakhlallah2*

    1University of Leeds, M Sc Biotechnology, UK

    2West Virginia University, USA

    *Corresponding author: Ajay Dhakal, Clinical Fellow, Department of Medicine, Roswell Park Cancer Institute, University at Buffalo, Elm and Carlton Streets, 14263, Buffalo, New York, USA

Submission: July 31, 2017; Published: September 05, 2017

DOI: 10.31031/NACS.2017.01.000502

Volume1 Issue1


Thisreview aims at giving an insight at some of the recent approaches in using the aptamer technology in formulating the chemotherapeutic agent, doxorubicin, so as to achieve its targeted delivery and reduce its non-specific cytotoxicity.

Abbreviations: SELEX: Systematic Evolution Of Ligands By Exponential Enrichment; DOX: Doxorubicin; PSMA: Prostate-Specific Membrane Antigen; EpCAM: Epithelial Cell Adhesion Molecule; NPs: Nanoparticles; SPIONs: Superparamagnetic iron oxide nanoparticles; MRI: Magnetic Resonance Imaging; QDs: Quantum Dots; MUC1: Mucin 1; PSMA: Anti-Prostate Specific Membrane Antigen; TLC: Thermally Cross-Linked

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137